canyon landscape

Abbvie M22-418

A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine


The purpose of this study is to see if the study drug, Atogepant, is safe and able to prevent breakthrough migraines when added to BOTOX in people with chronic migraine. This study is for research purposes only. This study will help the sponsor, AbbVie, to learn about the safety and effectiveness of Atogepant when added to BOTOX in participants with chronic migraine.

Open and enrolling subjects.
Phoenix, Arizona
Total Participants
Primary Sponsor